Our Strategy
Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity. Our lead product candidate, entospletinib (ENTO), is a selective spleen tyrosine kinase (SYK) inhibitor that has been tested in over 170 acute myeloid leukemia (AML) patients to date. Based on clinical results in a biomarker-defined patient subset we plan to initiate a registrational clinical trial in 2021. We are also developing KB-0742, a selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) for the treatment of MYC-amplified solid tumors. We have initiated a Phase 1/2 trial for KB-0742 and expect to report initial safety, PK and PD data from the dose escalation cohorts in the fourth quarter of 2021. In addition, we have multiple oncology discovery programs targeting dysregulated transcription factors.
Our Science:
Targeting dysregulated transcription factors in cancer
Addressing the complexity of oncogenic TRNs requires a sophisticated and holistic approach to targeting cancer biology. TRNs encompass hundreds of proteins that function in a coordinated fashion to orchestrate specific gene expression programs that control development and function of healthy cells. Dysregulated TRNs resulting from aberrant transcription factor expression or activity are frequently responsible for reprogramming healthy cells into cancerous tumor cells. We apply computational biology to map the TRNs and identify the critical nodes and gene expression signatures that drive cancer. We believe that these critical nodes present attractive targets for therapeutic intervention using a biomarker-driven precision medicine strategy.
Product Engine
Our product engine includes four interconnected components, each of which is informed by our translational expertise, that enable efficient, hypothesis-driven clinical development of our product candidates:
Identify gene expression signature of selective TRN modulation
Conduct high throughput SMM screens in tumor cell lysates to identify selective TRN modulators
Refine pharmacological properties to yield attractive product development candidates
Hypothesis driven clinical trials to deliver proof of concept early in the development process
Conduct high throughput SMM screens in tumor cell lysates to identify selective TRN modulators
Hypothesis driven clinical trials to deliver proof of concept early in the development process
Pipeline/Programs
We have developed a robust clinical and preclinical pipeline through a combination of internal discovery efforts and focused asset acquisition. The following chart summarizes our product pipeline, including our lead product candidate, ENTO, as well as our discovery programs and our next anticipated milestones.
Product Candidate
Discovery
IND-Enabling Studies
Phase 1 Trial
Phase 2 Trial
Phase 3 Trial
2021: Initiate NPM1 mt AML registrational Phase 2/3 clinical trial pending regulatory feedback from planned meetings
Q4 2021: Initial safety, PK and PD data from dose escalation cohorts
TRN
Indication
Discovery
IND-Enabling Studies
Phase 1 Trial
Phase 2 Trial
Phase 3 Trial
MYB
AML
First IND filing in 2022 among these programs
ARv7
Prostate Cancer
IRF4
Multiple Myeloma
ASCL1
Small Cell / Neuroendocrine Cancers
Careers
JOIN OUR TEAM
We are looking for innovative team members who share our passion for transformative science paired with unparalleled execution.
See our current list of openings below or submit your resume to careers@kronosbio.com.
“
we’re building the highway, not filling potholes”
‟we’re building the highway, not filling potholes”
Director, Biology